Blanche pledges action on stopping mail order mifepristone
Blanche Vows to Halt Mail-Order Mifepristone Distribution
Commitment to Reversing Biden-Era Policy
Blanche pledges action on stopping mail - Acting Attorney General Todd Blanche made a public commitment on Wednesday to pursue measures that would prevent abortion medication from reaching patients via postal delivery. During discussions with Republican lawmakers, he assured them that mifepristone would receive priority attention should he receive confirmation for his position, though he stopped short of outlining exact steps he would take.
The Trump administration has expressed opposition to a policy established under President Biden that permitted the abortion pill to be mailed directly to consumers. Blanche indicated that the Department of Justice may conduct a thorough examination of this regulatory framework as part of its broader review efforts.
"You know, I've seen video myself of what appears to be pills coming even from overseas to young women, and doesn't matter who applies for it, anybody can get it. There's no instructions; they just come dumped out of a little plastic bag, and and it's wrong," Blanche continued. "And I very much commit our resources to stopping this."
Context of the Mail-Order Debate
Medication abortion represents the most frequently utilized method for ending pregnancies in the United States. Critics of abortion rights have increasingly voiced concerns regarding the widespread accessibility of mifepristone, which functions as one component of a two-drug regimen commonly employed for medical termination procedures.
Following the Supreme Court's decision to overturn Roe v. Wade, the Biden administration implemented a permanent change in 2023 that eliminated the requirement for patients to receive mifepristone in person. This regulatory shift proved significant, particularly when combined with protective legislation in blue states that shields healthcare providers from legal prosecution.
These developments have enabled women to continue accessing abortion services even as numerous conservative states have either prohibited or substantially restricted the operation of abortion clinics within their borders.
Legal Challenges and FDA Review
While the Trump administration has maintained the existing Biden-era regulations, keeping the matter relatively quiet in public discourse, the policy has generated considerable frustration among anti-abortion legislators and advocacy organizations. Republican senators have urged Blanche to resolve an ongoing legal dispute involving Louisiana, which filed a lawsuit against the Food and Drug Administration challenging the mail-order distribution of mifepristone.
The U.S. Court of Appeals for the Fifth Circuit has scheduled oral arguments for September to consider this case. Meanwhile, anti-abortion coalitions have launched an intensive campaign pressuring the Department of Justice to cease defending the Biden administration's position. In recent legal submissions, the department has requested that courts either dismiss or temporarily halt state-level lawsuits, citing in part the FDA's ongoing safety assessment of the medication.
"We are not in any way defending what Biden and what his administration did," Blanche said.
"For the first time in a decade, HHS and the FDA are actually taking a real look at what's happening with some of these abortion pills and whether they're actually safe or not," Blanche added.
Looking Ahead
The precise schedule and current status of the FDA's comprehensive review remain uncertain. According to one administration official, the evaluation process is expected to require approximately six months to conclude, although preliminary findings may become available sooner than anticipated.
"We want to get to a good result, consistent with President Trump's administrative directive and priorities, and we very much believe that the Biden rules were wrong," Blanche said.
As the legal and regulatory landscape continues to evolve, Blanche's commitment signals a potential shift in how the federal government approaches the distribution of abortion medication through postal channels. The outcome of both the Louisiana lawsuit and the FDA safety review will likely play crucial roles in determining the future of mail-order mifepristone access across the nation.